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Gene therapy, in its simplest form, involves the introduc- an adenosine deaminase changes a CAG codon (argi-
nine) to a CIG codon (glutamine), resulting in isoformstion of a gene encoding a normal version of a defective
or a missing protein into cells. However, there are many with different calcium-permeability properties (Smith
and Sowden 1996; Ashkenas 1997).types of acquired and inherited diseases or of domi-
nantly acting inherited traits for which gene replacement Although apoB48 contains the N-terminal 48% of
is not possible. Treatment of infectious diseases such as apoB100, the two proteins have divergent metabolic
hepatitis or HIV may require inactivation of a virus, fates. The portions of apoB100 that mediate binding
and, in some cancers, a gene may be overly active or to the low density lipoprotein (LDL) receptor are ab-
may have altered properties, owing to mutations. In such sent in apoB48, as are the domains that bind apolipo-
cases, it may be more appropriate to borrow the tech- protein(a) (apo[a]) to form the atherogenic lipoprotein
niques of gene therapy to modify or to destroy speciﬁc Lp(a) (Utermann 1995). The intestine secretes dietary
mRNAs, to achieve a therapeutic endpoint. One form lipids in the form of the apoB48-containing chylomi-
of message therapy involves speciﬁc modiﬁcation of an crons, which are converted in the plasma to chylomi-
mRNA, to take advantage of naturally occurring cron remnants, through lipolysis. The remnants are
mRNA-editing activity. Other methods include targeted taken up into the liver via binding of apolipoprotein
removal of a speciﬁc mRNA, typically by use of ribo- E (apoE) to the LDL receptor-related protein (LRP)
zyme or antisense technology. (Herz and Willnow 1995). On the other hand, the liver
secretes lipids in the form of very low density lipopro-
mRNA Editing tein (VLDL), which contains both apoB100 and apoE.
VLDL is converted to LDL, of which the sole apolipo-
Apolipoprotein B (apoB), a protein contained in lipo-
protein is apoB100, and, thus, is a ligand only for the
protein particles secreted by the liver and the intestine,
LDL receptor. ApoE has a higher afﬁnity for the LDL
circulates in the human body in two forms, apoB100 and
receptor than does apoB100, and the apoB48-con-
apoB48 (Young 1990). Human liver synthesizes only
taining lipoproteins have a much shorter half-life in the
apoB100, whereas the intestine synthesizes apoB48.
plasma than do the apoB100-containing lipoproteins
ApoB48 mRNA, which encodes the N-terminal 48%
(Young 1990).of the apoB100 open reading frame, is derived from
The relatively slow clearance of plasma apoB100-con-apoB100 mRNA. ApoB48 is generated by speciﬁc post-
taining lipoproteins and the requirement of the presencetranslational editing of a cytidine residue, to change a
of apoB100 for synthesis of Lp(a) suggest that it mightCAA codon (glutamine) to a UAA stop codon. The edit-
be clinically desirable to induce higher expression ofing process is performed by a complex of proteins, of
apoB48, at the expense of apoB100. Ectopic expressionwhich the catalytic subunit is designated the apoB
of apobec-1 may be a promising strategy for messagemRNA-editing enzyme (apobec-1) (Ashkenas 1997;
therapy, depending on whether (1) apobec-1 is sufﬁcientChan et al. 1997). A similar editing process occurs for
to confer apoB mRNA-editing activity in the liver (i.e.,the glutamate receptor, expressed in the brain, in which
is it the rate-limiting step in editing) and whether (2) a
shift toward more apoB48 secretion will reduce plasma
VLDL, LDL, and Lp(a) levels. Recombinant adenovirusReceived August 8, 1997; accepted for publication August 15, 1997.
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rat apobec-1, into normal mice nearly eliminated variety of hypercholesterolemic conditions, for which
the lowering of plasma LDL and Lp(a) levels is the goal.apoB100 production (Teng et al. 1994) and reduced
LDL levels. Both of these effects were transient, as com- One potential advantage, in comparison with the over-
expression of LDL receptors, for example, is that hepaticmonly is seen when transgenes are expressed from a
recombinant adenovirus, in immunocompetent mice expression of apobec-1 is not likely to result in sudden
increases in cholesterol uptake into the liver, as has been(e.g., see Barr et al. 1995; Kozarsky et al. 1996; Wads-
worth et al. 1997). observed in animals overexpressing the LDL-receptor
transgene (Kozarsky et al. 1994). Of even more impor-A test of the effects of heightened apobec-1 expression
on Lp(a) metabolism was not possible in normal mice, tance, in the case of LDL receptor–deﬁcient FH, apobec-
1 would not stimulate an immune response (it normallybecause they do not express apo(a) and because apo(a)
binds to human, but not to mouse, apoB100. However, is expressed in the intestine), whereas the LDL receptor
might, particularly in an FH patient who expresses noa transgenic mouse that expresses both human apoB100
and human apo(a) has been generated and thus makes LDL receptor protein (Kozarsky et al. 1996). However,
there is the potential drawback that mice and rabbitsLp(a) (Linton et al. 1993; Callow et al. 1994). This
transgenic mouse was injected with a recombinant ade- that are transgenic for apobec-1 can develop hepatocel-
lular carcinoma and dysplasia (Yamanaka et al. 1995).novirus expressing apobec-1; as a consequence, there
was increased editing of both the transgenic human and Because normal mice express apobec-1 in the liver with-
out developing dysplasia, it is possible that these compli-the endogenous mouse apoB mRNAs (Hughes et al.
1996). This lowered LDL levels and, furthermore, low- cations could be avoided by reduction of apobec-1
transgene expression. These hepatic symptomsmay ariseered Lp(a) levels, suggesting that apobec-1 may be a
therapy for the reduction of Lp(a), thus reducing the from editing of other mRNA substrates; a few mRNAs
with sequences homologous to those that determine ed-risk of atherosclerosis in humans.
To determine whether apobec-1 could confer apoB iting speciﬁcity in apoB mRNA have been identiﬁed.
Two of these mRNAs, encoding a tyrosine kinase (Ya-mRNA-editing activity on a liver that, like human liver,
normally does not express apobec-1, recombinant ade- manaka et al. 1995) and a novel translational repressor
(Yamanaka et al. 1997), indeed are edited in the liversnovirus was used in normal rabbits (Hughes et al. 1996)
or in LDL receptor–deﬁcient rabbits (Kozarsky et al. of apobec-1 transgenic mice. The alterations in these
and other genes are likely to be responsible for the devel-1996). In both studies, the livers of rabbits edited apoB
mRNA, after injection with a recombinant adenovirus opment of dysplasia; thus, speciﬁcity of the apoB
mRNA-editing activity is crucial to the determinationencoding apobec-1, demonstrating that hepatic apobec-
1 expression is sufﬁcient to confer editing activity. A of the speciﬁcity of gene therapy. Careful control over
expression levels and/or engineering of the editing en-rabbit model of the human disease familial hypercholes-
terolemia (FH) was used to determine whether hepatic zyme may be needed in order to make this strategy safe
and effective.expression of apobec-1 would be therapeutic, that is,
would result in lowered LDL levels. The rabbit model
was the LDL receptor–deﬁcient Watanabe heritable hy- Oligonucleotide Therapeutics
perlipidemic (WHHL) rabbit, which, like FH patients,
is defective in LDL-receptor activity and exhibits high An alternative strategy for mRNA-targeted gene ther-
apy is the use of site-directed oligonucleotide therapeu-levels of circulating LDL and premature atherosclerosis.
Expression of apobec-1 in WHHL-rabbit liver via a re- tics, such as ribozymes or antisense oligonucleotides.
Both agents target RNA in a sequence-speciﬁc mannercombinant adenovirus resulted in increased levels of cir-
culating apoB48 and in increased apoB48 content in and have the potential to modify RNA or to abrogate
translation by mediation of RNA degradation. AntisenseVLDL. The VLDL cholesterol levels were reduced, ac-
companied by alterations in VLDL size and by modest oligonucleotides bind with target RNA and inhibit
translation through several possible mechanisms, suchreductions in total plasma cholesterol (Kozarsky et al.
1996). Evidence of a therapeutic effect of apobec-1 over- as by inhibition of ribosomal readthrough or by activa-
tion of the cellular enzyme RNaseH. Ribozymes are en-expression, in the context of increased plasma LDL lev-
els, was conﬁrmed by use of the LDL-receptor knockout zymatic RNA molecules capable of catalyzing sequence-
speciﬁc RNA cleavage (Cech 1992). RNA cleaved by amouse. In the mouse, increased apobec-1 activity in the
liver was correlated with an Ç30% reduction in apoB- ribozyme becomes unstable and is not translated. Se-
quence speciﬁcity is conferred by standard Watson-containing lipoprotein cholesterol and with signiﬁcantly
decreased LDL levels, as measured by nondenaturing Crick base pairing. By alteration of the ribozyme or the
antisense target-recognition sequences, any cellular orgradient-gel electrophoresis (Teng et al. 1997).
Gene therapy by introduction of the apoB mRNA viral RNAmay be targeted, in principle. Diseases associ-
ated with aberrant or viral expressed RNA, such as can-editase into the liver has the potential to be useful in a
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cer, restenosis, and HIV, are the current focus of oligo- ral RNA targets, and efﬁcacy has been demonstrated,
against viral RNA expressed by the inﬂuenza A virusnucleotide-therapy research. However, recent reports of
RNA repair or alternate splicing, with oligonucleotides, (Tang et al. 1994), the bovine leukemia virus (Cantor
et al. 1993), and HIV (Sarver et al. 1990). AIDS, re-expand the future possibilities to include diseases associ-
ated with loss of protein function through genetic muta- sulting fromHIV infection, remains a signiﬁcant medical
concern, and enormous effort has been made in the de-tion. Ribozymes and antisense oligonucleotides also may
be useful for the direction of alternate processing or for velopment of ribozymes as therapeutics against this vi-
rus. The ﬁrst reports of the efﬁcacy of ribozymes againstthe repair of mRNA targets. Sullenger and Cech (1994)
demonstrated this by adapting the splicing activity of a HIV emerged shortly after the discovery of the ribozyme.
Sarver et al. (1990) targeted a plasmid-encoded ribo-group I ribozyme, to recognize and to correct a mutated
lacZ gene in E. coli. Jones et al. (1996) modiﬁed the zyme to the gag region of HIV. Upon infection with
HIV, CD4/ HeLa cells, transfected with the ribozymesystem so that targeted mRNA would be tagged by the
ribozyme with a novel exon 3, to allow an assessment plasmid, showed a reduction in viral gag mRNA and an
inhibition of viral replication, as measured by a reduc-of efﬁcacy and speciﬁcity. Results indicated a high de-
gree of target-speciﬁc tagging, but many additional non- tion in the p24 viral envelope antigen. Such early efforts,
using transient plasmid transfections, cell lines, and lab-targeted cellular mRNA were tagged. Efforts are under-
way to improve the site speciﬁcity of this technology. oratory-adapted HIV isolates, increasingly have given
way to the use of stable viral vectors for the expressionBecause of their small size, multiple antisense oligonu-
cleotides or ribozymes, aimed at multiple regions of a of ribozymes, primary hematopoietic cells, and clinical
isolates of the virus (Wong-Staal 1995; Bauer et al.target RNA, can be incorporated into current gene-ther-
apy vectors. The engineering of such redundancy into 1997). In one report, retroviral constructs expressing a
hairpin ribozyme conferred resistance to multiple strainsthe vectors could allow multiple mediators of a disease
to be suppressed and might prevent the emergence of of HIV, in peripheral blood lymphocytes (Leavitt et al.
1994). Speciﬁcity was demonstrated by the lack of inhi-escape mutants, in viral targets (such as HIV). Target-
speciﬁc effects of antisense oligonucleotides have been bition of a closely related virus, HIV-2, which lacks the
U5 long terminal repeat target site. Hammerhead ribo-demonstrated in many cell and animal model systems
(Agrawal 1996; Akhtar and Agrawal 1997). There are zymes targeting HIV U5 or tat regions also have proved
effective (Dropulic et al. 1992; Sun et al. 1995). Othernumerous reports of ribozyme efﬁcacy in cell-culture
models of human disease (Christoffersen and Marr investigators have shown that a hammerhead-ribozyme
dimer targeting two sites, in HIV tat and rev mRNA,1995), with signiﬁcant focus on cancer and viral targets.
The potential to target virtually any mRNA has al- protects T cells. In this case, the mechanism was demon-
strated by inclusion of an inactive ribozyme construct,lowed several groups to identify the growth factors, cell-
cycle regulators, and apoptosis mediators necessary for which showed signiﬁcantly less protection (Zhou et al.
1994).tumor growth and metastasis. Czubayko et al. (1994)
used ribozymes to demonstrate a crucial role for the Several groups are assessing the technical challenges
involved in isolating and transducing hematopoietic pro-growth factor pleotrophin (PTN) in human melanoma
cells. Melanoma cell lines stably transfected with a plas- genitor cells (HPC) with ribozyme-expressing vectors
against HIV. Gene therapy directed to HPC, which givesmid expressing either of two ribozymes targeted to PTN
showed signiﬁcant reduction in PTN secretion, reduced rise to all lymphocytic and myelocytic cell lineages, may
offer an attractive strategy for a number of genetic dis-soft agar colony–forming ability, and an inability to
form tumors in athymic nude mice. Speciﬁcity of the eases. Yu et al. (1995) transduced HPC, obtained from
fetal cord blood, with a retroviral vector expressing aribozymes was demonstrated by comparison of the efﬁ-
cacy in cell lines expressing a cDNA for either PTN or hairpin ribozyme and demonstrated protection against
a macrophage-tropic strain of the HIV virus, in thea closely related growth factor (midkine [MK]) with
50% homology to PTN but lacking the PTN target sites. differentiated progeny. More recently, Bauer et al.
(1997) transduced HPC, obtained from the peripheralWhereas both ribozymes reduced PTN and the colony-
forming ability in PTN-expressed cells, neither ribozyme circulation of adults, with the tat and rev dimer-ribo-
zyme retrovirus described above and observed signiﬁ-had an effect on colonies in MK-expressing cells. In
addition, no ribozyme efﬁcacy was observed with inac- cant protection against a primary clinical isolate and a
monocytotropic lab isolate of HIV.tive ribozyme constructs. The group then used the ribo-
zyme constructs to establish a set of human melanoma The ability to downregulate mRNA coding for cell-
cycle regulators, apoptotic mediators, growth factors,cell lines with different levels of PTN. A correlation was
observed between ribozyme-mediated PTN levels and etc., makes oligonucleotide gene therapeutics attractive
for applications to such diseases as cancer, restenosis,angiogenesis and metastasis (Czubayko et al. 1996).
Ribozymes also are attractive therapeutics against vi- and other proliferative disorders. In viral diseases, ribo-
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Perkins J, et al (1995) Strain related variations in adenovi-zymes and antisense oligonucleotides are attractive for
rally mediated transgene expression from mouse hepato-their potential to target multiple viral RNAs, including
cytes in vivo: comparisons between immunocompetent andthe viral genome, prior to reverse transcription and inte-
immunodeﬁcient inbred strains. Gene Ther 2:151–155gration, in the case of RNA viruses such as HIV. The
Bauer G, Valdez P, Kearns K, Bahner I, Wen SF, Zaia JA,capabilities of oligonucleotide gene therapy, demon-
Kohn DB (1997) Inhibition of human immunodeﬁciencystrated against viral and acquired diseases, likely will be
virus-1 (HIV-1) replication after transduction of granulocyte
extended to heritable genetic diseases. Some of these colony-stimulating factor-mobilized CD34/ cells from HIV-
diseases, such as Huntington disease and related neuro- 1-infected donors using retroviral vectors containing anti-
degenerative disorders, are characterized by the expres- HIV-1 genes. Blood 89:2259–2267
sion of mutant mRNAs encoding dominant negative CallowMJ, Stoltzfus LJ, Lawn RM, Rubin EM (1994) Expres-
proteins of unknown function (Paulson and Fischbeck sion of human apolipoprotein B and assembly of lipopro-
1996). Ribozymes or antisense oligonucleotides could tein(a) in transgenic mice. Proc Natl Acad Sci USA 91:2130–
2136readily be designed to target these mRNAs and may
Cantor GH, McElwain TF, Birkebak TA, Palmer GH (1993)offer important strategies for the treatment of these dis-
Ribozyme cleaves rex/tax mRNA and inhibits bovine leuke-eases.
mia virus expression. Proc Natl Acad Sci USA 90:10932–
10936Conclusions
Cech TR (1992) Ribozyme engineering. Curr Opin Struct Biol
Gene therapy at the mRNA level has several advan- 2:605–609
Chan L, Chang BH, Nakamuta M, Li WH, Smith LC (1997)tages over gene therapies in which the primary purpose
Apobec-1 and apolipoprotein B mRNA editing. Biochim Bi-is the addition of a protein product. First, message ther-
ophys Acta 1345:11–26apy is versatile; it is able to be widely applied to both
Christoffersen R, Marr J (1995) Ribozymes as therapeuticinherited and acquired diseases. It is performed on so-
agents. J Med Chem 9:2023–2037matic cells, most of which are able to be transduced by
Czubayko F, Riegel AT, Wellstein A (1994) Ribozyme-tar-use of one or more current vectors, and it avoids the
geting elucidates a direct role of pleiotrophin in tumorcomplicated ethical issues that would be involved if
growth. J Biol Chem 269:21358–21363
transgenes were introduced into germ cells. Further- Czubayko F, Schulte AM, Berchem GJ, Wellstein A (1996)
more, these therapies have the potential to be reversible Melanoma angiogenesis and metastasis modulation by ribo-
and thus can be active only when needed. Inactivation zyme targeting of the secreted growth factor pleiotrophin.
may occur by the deliberate obtaining of transient ex- Proc Natl Acad Sci USA 93:14753–14758
pression, through introduction of a nonintegrating vec- Dropulic B, Lin NH, Martin MA, Jeang KT (1992) Functional
tor into cells with a limited half-life or by use of regulat- characterization of a U5 ribozyme: intracellular suppression
able promoters. In addition, message therapy can of human immunodeﬁciency virus type 1 expression. J Virol
66:1432–1441circumvent limitations in the duration of transgene ex-
Funahashi T, Giannoni F, Depaoli A, Skarosi S, Davidson Npression, by avoidance of the development of an immune
(1995) Tissue-speciﬁc, developmental and nutritional regu-response to the transgene, either because the protein
lation of REPR gene expression. J Lipid Res 36:414–428product is normally expressed in patients (but in a differ-
Herz J, Willnow T (1995) Lipoprotein and receptor interac-ent tissue of the body, as with apobec-1) or because the
tions in vivo. Curr Opin Lipid 6:97–103transgene directs synthesis of an RNA/oligonucleotide
Hughes SD, Rouy D, Navaratnam N, Scott J, Rubin EMand not of a protein. Limitations primarily involve the
(1996) Gene transfer of cytidine deaminase apoBEC-1 low-speciﬁcity of the mRNA modiﬁcations, which may be
ers lipoprotein(a) in transgenic mice and induces apolipo-
controlled by careful regulation of levels of expression protein B editing in rabbits. Hum Gene Ther 7:39–49
(apobec-1) or by direct engineering of speciﬁcity (ribo- Jones JT, Lee SW, Sullenger BA (1996) Tagging ribozyme reac-
zymes and oligonucleotides). Thus, mRNA-directed tion sites to follow trans-splicing in mammalian cells. Nat
therapy may be a useful addition to the collection of Med 2:643–648
strategies for gene therapy for human disease. Kozarsky KF, Jooss K, Donahee M, Strauss JF III, Wilson JM
(1996) Effective treatment of familial hypercholesterolaemia
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